TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2014

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer.

D Ross Camidge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.